(Reuters) The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab’s real-world effectiveness.
Home
—
Global Center for Health Security
—
The Transmission
—
Omicron COVID booster cuts hospitalization in over 65s, Israeli study finds
Omicron COVID booster cuts hospitalization in over 65s, Israeli study finds
- Published Jan 9, 2023